The aim of the project is to develop an innovative form of modified release Furazidine (MR), used in the treatment of acute and recurrent urinary tract infection (ZUM). The product will be the Applicant’s response to the growing need for effective and safe medicine, while ensuring the convenience of use in the treatment of ZUM. Only in Poland a few million people are treated each year due to urinary tract infections, but due to the increasing rate of drug resistance causing ZUM microorganisms, treatment with available medicines proves to be less effective. The choice of Furazidine is supported by its effectiveness and safety. The effectiveness is due to the high sensitivity of the micro-organisms to this substance. Safety is confirmed by adverse reactions statistics – only isolated cases with multimillion-dollar sales of Furazidine medicines. Despite the above-mentioned advantages of Furazidine due to its unfavourable pharmacokinetic properties, it has not gained much interest outside the countries of Wed-East Europe. The immediate-release drug (IR) available on the market requires the use of 2 tablets 3-4 times a day to maintain adequate plasma concentrations. The project plans to develop a form of medicine with modified, prolonged release, which will provide patients with effective, safe and convenient ZUM therapy – a modified release profile will allow you to take 1 tablets a day. The objectives will be achieved through the implementation of the 4 phases of the project, which will take place chronologically as follows: — formulation (stage 1), – Pilot pharmacokinetic (stage 3), – Reformation (phase 2), in accordance with Article 25 of Regulation No 651/2014 of the European Commission of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 108, p. I'm sorry. EU L 187/1 of 26.06.2014)